Cortechs.ai | Diagnostic efficacy of structural MRI in patients with AD

Diagnostic efficacy of structural MRI in patients with AD

Diagnostic efficacy of structural MRI in patients with mild-to-moderate Alzheimer disease: automated volumetric assessment versus visual assessment

The automated volumetric assessment tool had moderate sensitivity (63.3%) and high specificity (100%) in differentiating patients with mild-to-moderate AD from control subjects. Visual inspection showed sensitivity of 63.3% and specificity of 92.0%. The diagnostic performance was not significantly different between the two methods (p =0.536–0.906). Intraobserver reliability for visual inspection was 0.858 and 0.902 for the two reviewers, and interobserver reliability was 0.692–0.780. (2016).

[button]Download[/button]

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top